When the Recon finally goes on sale, it’ll give customers an EV that's truly capable off-road. It'll also help the company play catch-up with competitors who are already stealing market share ...

The Recon was unveiled back in 2022 when it was meant to herald a new electric era for the historic American brand. The EV was heavily inspired by models like the XJ-generation Jeep Cherokee and ...

A new Ghost Recon game has leaked online and it’s apparently going to release soon. Tom Clancy’s Ghost Recon began back on November 13, 2001 with the release of a game of the same name on PC ...

It's been more than two years Jeep first floated its Recon nameplate past us, teasing it as aa boxy, electric SUV with an off-road focus. Now, its time to shine as a production model is nearly ...

Enhertu achieved a median progression-free survival of 13.2 months versus 8.1 months for chemotherapy, with a higher objective response rate of 62.6% compared to 34.4%. This summary was ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Growth is expected to be supported by ENHERTU's continued expansion. Profit attributable to owners of the company for FY2024 was revised upward by ¥15 billion to ¥240 billion, driven by improved ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

Jeep's new inbound all-electric Recon off-roader could be ready to enter production by February, according to a recent report. MoparInsiders reports that Stellantis bumped up the Recon EV's ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...